LipidRescue® Therapy has saved countless lives. The peer-reviewed medical literature has dozens of published reports supporting its potential efficacy in treating LAST and various types of NODO.
Dr. Guy Weinberg discovered that LipidRescue® Therapy (infusing a lipid emulsion) rapidly reverses severe LAST in rats and dogs.
The journal Anesthesiology published thefirst case report of LipidRescue® Therapysaving a patient with LAST.
Annals of Emergency Medicine published the first report of LipidRescue® Therapy in non-opiate drug overdose.
Advisories published by the American Society of Regional Anesthesia and Pain Medicine and the Association of Anesthetists of Great Britain and Ireland established LipidRescue® Therapy as first-line treatment for LAST.
The American Heart Association recommended LipidRescue® Therapy in LAST and other, specific types of drug overdose including certain types of NODO.
ResQ Pharma has received Orphan Drug designation from the FDA for use of LipidRescue® Therapy in the treatment of LAST. Following a preNDA meeting with the FDA in December 2020, ResQ anticipates filing its NDA in 2021 for a kit to treat LAST